参考资料：[1]Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies. Retrieved September 15, 2020, from https://www.neogene.com/neogene-therapeutics-raises-110-million-series-a-financing-to-develop-next-generation-fully-personalized-neo-antigen-t-cell-receptor-tcr-therapies/ 版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「创鉴汇」微信公众号回复“转载”，获取转载须知。 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。